Copyright
©The Author(s) 2019.
World J Gastrointest Endosc. Feb 16, 2019; 11(2): 124-132
Published online Feb 16, 2019. doi: 10.4253/wjge.v11.i2.124
Published online Feb 16, 2019. doi: 10.4253/wjge.v11.i2.124
Total | Pillcam® SB3 | Pillcam® SB2 | P value | |
Patients | 260 | 130 | 130 | |
Age (yr) | 67.1 ± 10.4 | 68.3 ± 11.1 | 65.9 ± 9.5 | 0.061 |
Male gender | 245 (94.2%) | 122 (93.8%) | 123 (94.6%) | 0.790 |
BMI (kg/m2) | 30.3 ± 6.3 | 30.1 ± 6.1 | 30.5 ± 6.4 | 0.618 |
Inpatient status | 32 (12.3%) | 19 (14.6%) | 13 (10.0%) | 0.257 |
Diabetes | 119 (45.8%) | 69 (53.1%) | 50 (38.5%) | 0.018 |
Opioid use | 73 (28.1%) | 31 (23.8%) | 42 (32.3%) | 0.129 |
GTT (min) | 39.6 ± 47.4 | 37.7 ± 40.4 | 41.4 ± 53.4 | 0.971 |
SBTT (min) | 220.4 ± 85.7 | 233.1 ± 82.4 | 208.8 ± 87.3 | 0.554 |
Inadequate preparation | 33 (12.7%) | 15 (11.5%) | 18 (13.8%) | 0.576 |
Incomplete exam | 34 (13.1%) | 22 (16.9%) | 12 (9.2%) | 0.066 |
- Citation: Aasen TD, Wilhoite D, Rahman A, Devani K, Young M, Swenson J. No significant difference in clinically relevant findings between Pillcam® SB3 and Pillcam® SB2 capsules in a United States veteran population. World J Gastrointest Endosc 2019; 11(2): 124-132
- URL: https://www.wjgnet.com/1948-5190/full/v11/i2/124.htm
- DOI: https://dx.doi.org/10.4253/wjge.v11.i2.124